Clinical Trial Update: Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis [Phase 4]

View source ↗

Summary

This Phase 4 trial update indicates that the study evaluating the long-term effect of fingolimod on circulating immunocompetent mononuclear cells in relapsing-r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• GILENYA (FINGOLIMOD HCL)

Snippet

Sponsor: Heinrich-Heine University, Duesseldorf | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 4 | Status: TERMINATED